Form 4: Pliant Therapeutics Executive Hans Hull Reports Stock Vesting and Share Acquisitions

Hans Hull, Chief Business Officer of Pliant Therapeutics, reports the vesting of performance-based stock units and acquisitions through an employee stock purchase plan.

Summary

• Hans Hull, Chief Business Officer of Pliant Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On July 9, 2024, 19,337 shares of common stock vested due to the achievement of performance criteria related to the company's total shareholder return relative to the Nasdaq Biotechnology Index.
• These shares were part of a grant of 70,312 performance-vested stock units from July 28, 2022.
• Hull also acquired 1,488 shares through the Employee Stock Purchase Plan.
• Following these transactions, Hull directly owns 237,394 shares of common stock.
• Hull also has indirect ownership through The Sloger Hull Family Trust (3,821 shares), a trust for a minor child (Child A Trust) (13,985 shares), and another trust for a minor child (Child B Trust) (13,985 shares).
• Hull disclaims beneficial ownership of shares held in the trusts except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of shares indicates the achievement of performance goals, and the acquisition of shares through the employee stock purchase plan suggests confidence. However, it's a routine filing.

Positives

• The vesting of performance-based stock units suggests that Pliant Therapeutics has met certain performance targets related to shareholder return.
• Acquisition of shares through the Employee Stock Purchase Plan indicates confidence in the company's future.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of performance-based stock units suggests an expectation of continued positive performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates changes in Hans Hull's ownership of Pliant Therapeutics stock.

Stakeholder Impact

• The vesting of performance-based stock units could positively impact shareholder sentiment.
• The filing provides transparency to shareholders regarding insider transactions.

Key Dates